Switching to latanoprost monotherapy for 24 weeks in glaucoma patients

European Journal of Ophthalmology

Volumn 14, Issue 5, 2004, Pages 401-406

  Takahashi, Imako ^a,b   Tanaka, M ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

Author keywords

Intraocular pressure; Latanoprost; Monotherapy; Unoprostone; antagonist

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARTEOLOL; LATANOPROST; NIPRADILOL; TIMOLOL; UNOPROSTONE ISOPROPYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EYELID DISEASE; EYELID HYPERPIGMENTATION; EYELID HYPERTRICHOSIS; FEMALE; FOLLOW UP; GLAUCOMA; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TIME SERIES ANALYSIS;

EID: 8344223670     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210401400507     Document Type: Article

References (14)

1. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995; 102: 1743-52.
2. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37.
3. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 1996; 103: 138-47.
4. Camras CB, Alm A, Watson P, Stjernschantz J, Latanoprost Study Group. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996; 103: 1916-24.
5. Sakurai M, Araie M, Oshika T, et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol 1991; 35: 156-65.
6. Sakurai M, Araie M, Oshika T, et al. Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbits. Jpn J Ophthalmol 1993; 37: 252-8.
7. Thieme H, Stumpff FF, Ottlecz A, et al. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2001; 42: 3193-201.
8. Serle JB, Podos SM, Kitazawa Y, et al. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 1998; 42: 95-100.
9. Susanna R, Grampian J Jr, Borges AS Jr, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001; 108: 259-63.
10. Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6-month data. Am J Ophthalmol 2002; 133: 1-10.
11. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol 1998; 126: 390-9.
12. Wand M. Latanoprost and hyperpigmentation of the eyelashes. Arch Ophthalmol 1997; 115: 1206-8.
13. Johnston M. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-7.
14. Yamamoto T, Kitazawa Y. Iris color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997; 6: 430-2.